Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan for Uric Acid Lowering in Children with Proteinuric Nephropathies
NCT05402397Phase 4Completed
- Sponsor
- Hospital General de Niños Pedro de Elizalde
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of losartan, sponsored by Hospital General de Niños Pedro de Elizalde. Primary endpoint: Serum uric acid levels at 30 days. Started Jul 2022; status: completed.
02
Drugs
losartan
Beyond the preview
Go deeper on NCT05402397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05402397.